Comparative Pharmacology
Head-to-head clinical analysis: CROLOM versus GASTROCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROLOM versus GASTROCROM.
CROLOM vs GASTROCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CROLOM is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors, blocking estrogen-mediated signaling in target tissues, thereby inhibiting growth of hormone-sensitive breast cancer cells.
Mast cell stabilizer; inhibits degranulation of mast cells and release of histamine and other inflammatory mediators.
2 capsules (each containing 40 mg cromolyn sodium) orally 4 times daily, 30 minutes before meals and at bedtime.
200 mg orally four times daily, 30 minutes before meals and at bedtime.
None Documented
None Documented
Terminal half-life 8-12 hours in normal renal function; extended to 20-30 hours in severe impairment
Terminal elimination half-life is approximately 1–1.5 hours following intravenous administration. The apparent half-life after oral inhalation is longer due to slow absorption from the lungs, but systemic half-life remains short, requiring frequent dosing for sustained effect.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Primarily excreted unchanged in bile and feces via enterohepatic circulation; renal excretion accounts for approximately 1-2% of an oral dose. After intravenous administration, about 50% is excreted unchanged in urine within 48 hours.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer